Abstract: This invention discloses a rubbery polymer which is comprised of repeat units that are derived from (1) at least one conjugated diolefin monomer, and (2) at least one functionalized monomer having of the structural formula: 1

Abstract: Building materials based on polyisocyanate-impregnated lignocellulosic substrates provide increased strength and water, fire, insect, and fungi resistance compared to prior art building materials. At the same time, such building materials exhibit an aesthetically pleasing surface and can, therefore, be used in consumer visible applications (such as furniture) as well as in consumer invisible (such as door frames and stiles) applications.

Abstract: A non-aqueous laminate adhesive comprising a tertiary amino group-containing polyurethane resin (A) or a tertiary amino group- and carboxyl group-containing polyurethane resin (B) and a polyisocyanate curing agent. The resin (A) is obtained from (1) an active hydrogen group-containing compound comprising at least one or more kinds of tertiary amino group-containing glycols and (3) an organic polyisocyanate; and the resin (B) is obtained from (2) an active hydrogen group-containing compound comprising at least (a) one or more kinds of tertiary amino group-containing glycols and (b) one or more kinds of carboxyl group-containing glycols and (3) an organic polyisocyanate. The content of the tertiary amino group in the resin (A), the content of the tertiary amino group in the resin (B), and the carboxyl group in the resin (B) are each 0.001 to 1 mmol/g.

Abstract: The present invention relates to polyaspartates corresponding to the formula 1

Abstract: The present invention relates to polyaspartate mixtures containing

Abstract: Novel poly-o-hydroxyamides can be cyclized to give polybenzoxazoles which have a good diffusion barrier effect with respect to metals. The poly-o-hydroxyamides can be applied to a semiconductor substrate by customary techniques and converted into the polybenzoxazole in a simple manner by heating. This results in a good barrier layer with respect to diffusion of metals. This allows the diffusion barrier between conductor track and dielectric to be substantially dispensed.

Abstract: Resin composition comprising an epoxy resin having an epoxide functionality of at least 2.5, a cycloaliphatic epoxy resin, a phenol-formaldehyde novolac and aluminum acetylacetonate. The resin is heat stable and is suitable for fabrication of resin-rich mica tapes having low reactivity at ambient temperatures for good shelf life stability combined with high reactivity above 140° C. for application in press-cured tapes. The dissipation factors at room temperature to at least 200° C. are less than 3.0%.

Abstract: A method for the synthesis of poly(etherimide)s comprises the reaction of 4-halotetrahydrophthalic anhydride with an activating primary amine to yield an activated 4-halotetrahydrophthalimide. Activated 4-halotetrahydrophthalimide may then be aromatized and treated with the disodium salt of a bis(phenol) to yield an activated bisimide. The activated bisimide may then be directly treated with a diamine to yield poly(etherimide)s.

Abstract: The polyimide film of the present invention is produced in the following manner: polyamic acid made of a combination of a specific acid anhydride constituent and a specific diamine constituent are heated under a low-pressure circumstance for heat imidation, and the obtained imide is dissolved again in a solvent to be polyimide solution, then the polyimide solution is formed to be a film. In this manner, it is possible to provide a polyimide film essentially transparent and colorless, and has sufficient toughness to prevent occurrences of a crack or a break when the film is folded and creased by hand.

Abstract: To provide a coating composition of a soluble aromatic polyimide having good heat resistance and mechanical strength. As a soluble polyimide, a compound of the formula (I) in which R's represent independently from one another H, halogen, an alkyl group or an alkoxy group, or a substituted or unsubstituted phenyl group; A is a tetravalent aromatic group or a group of the formula (II) in which B is a covalent bond, a >C(R2)2 group, a carbonyl group, 0, S, a >SO2, group, a >Si (CH3)2 group, a >Si(C2H5)2 group, a >NR3 group or a bifunctional ether group in which R2 is a hydrogen atom or —C(R4)3, R3 is H, an alkyl group or an aryl group, and R4 is H, F or Cl; Ar is an aromatic nucleus or a group of the formula (III) in which Ar and B are the same as defined above, and each p is an integer of 0 to 10; m is an integer of 1 to 10 is used. The polyimide has a weight average molecular weight of 150,000 to 1,000,000.

Abstract: A process includes the steps of: casting or coating a polyamic acid organic solvent solution on a support and drying the polyamic acid organic solvent solution thereon, so as to form a partially cured and/or partially dried polyamic acid film; dipping the polyamic acid film in tertiary amine or a solution of tertiary amine, or coating tertiary amine or a solution of tertiary amine on the polyamic acid film; and drying the film while imidizing the polyamic acid. In another process, a chemical converting agent and a catalyst are mixed in an organic solvent solution of polyamic acid. After casting and heating the mixture on a support, a partially cured and/or partially dried polyamic acid film is detached from the support. The film contains, with respect to the remaining volatile component, not less than 50 parts of catalyst, not more than 30 parts of solvent, and not more than 20 parts of chemical converting agent and/or a chemical converting agent derived component.

Abstract: A amidoamine composition containing oligomeric amidoamine compounds having the structure: 1

Abstract: Thioester and selenoester generators, thioester and selenoester compounds, and related methods for their production are provided. The subject thioester and selenoester generators include an amino acid synthon having an N-terminal group joined to a C-terminal group through an organic backbone comprising one or more carbons. The organic backbone contains a carbon having a side chain anchored to a support through a nucleophile-stable linker and is lacking reactive functional groups. The organic backbone may include a target molecule of interest, such as an amino acid, peptide, polypeptide or other organic compound of interest, and/or the N- and/or C-termini can be elaborated using a variety of synthesis approaches to provide a target molecule of interest. The compounds and methods find a wide variety of uses, including use in thioester- or selenoester-based chemical ligation techniques.

Abstract: The invention is directed to substituted heterocyclic acyl-tripeptides useful as thrombin receptor modulators, their use in wound healing and preventing platelet aggregation. Pharmaceutical compositions comprising the substituted heterocyclic acyl-tripeptides of the present invention and methods of treating conditions mediated by the thrombin receptor are also disclosed.

Abstract: The invention is a process for the preparation of compounds of the Formula I: 1

Abstract: This invention relates to peptides useful for releasing active agent in the fields of diagnostics and drug delivery.

Abstract: The present invention concerns peptide nucleic acid (PNA) sequences, which are modified in order to obtain novel PNA molecules with enhanced properties.

Abstract: The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptide, in particular C35 peptide epitopes and C35 peptide epitope analogs, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides, in particular C35 peptide epitopes and C35 peptide epitope analogs, in immunogenic compositions or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene.

Abstract: Haemophilus adhesion and penetration proteins, nucleic acids, vaccines and monoclonal antibodies are provided.

Abstract: The present invention is directed to secreted and transmembrane polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The invention relates to compositions and methods for inhibiting cell proliferation, especially angiogenesis. The invention specifically relates to fusions of the extracellular domain of a fibroblast growth factor receptor (FGFR) with a heterologous oligomerization domain, such as that contained in an immunoglobulin, to provide potent FGFR antagonists.

Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

Abstract: The present invention relates to methods and products for the transepithelial systemic delivery of therapeutics. In particular, the invention relates to methods and compositions for the systemic delivery of therapeutics by administering an aerosol containing antibodies or conjugates of a therapeutic agent with an FcRn binding partner to epithelium of central airways of the lung. The methods and products are adaptable to a wide range of therapeutic agents, including proteins and polypeptides, nucleic acids, drugs, and others. In particular embodiments the conjugates are fusion proteins in which a therapeutic polypeptide is joined at its C terminal end through a peptide linker to the N terminal end of an immunoglobulin Fc gamma heavy chain, wherein the linker includes Glycine and Serine residues and is preferably 15 amino acids long.

Abstract: An IL-1&bgr; binding molecule, in particular an antibody to human IL-1&bgr;, especially a human antibody to human IL-1&bgr; is provided, wherein the CDRs of the heavy and light chains having amino acid sequences as defined, for use in the treatment of an IL-1 mediated disease or disorder, e.g. osteoarthritis, osteoporosis and other inflammatory arthritides.

Abstract: The invention relates to antibodies against VASP (vasodilator-stimulated phosphoprotein) which only bind VASP as an antigen when VASP is present in phosphorylated form, to hybridoma cells for their preparation, and to the use of the antibodies or antibody fragments as diagnostic agents and/or therapeutic agents.

Abstract: Protein polymers coated with a metal are provided. New methods are described for the preparation of tubulin-based microtubules such that they may be coated, by an electroless plating method, with gold particles of <20 nm in diameter without prior reaction with noble metal catalysts. The gold particle deposition can occur in suspension or on microtubules lying on a surface. Gold enhancement of the gold-particle coating and annealing results in ohmic conductance that is within a factor of ten of the resistivity of bulk gold. These methods are likely to be applicable to other protein polymers.

Abstract: Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.

Abstract: The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The inention in particular relates to the modification of erythropoietin (EPO) to result in erythropoietin proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.

Abstract: Methods and protected amino acids useful as building blocks (protected monomers) for the synthesis of peptides and proteins that are selectively modified at one or more side-chain hydroxyl groups. Azide-bearing protecting groups allow the selective deprotection of side-chain hydroxyl groups of amino acids after synthesis of a peptide. Reaction conditions for removal of the azide-bearing protecting group can be selected which are substantially orthogonal to those that will remove &agr;-amino protecting groups typically employed in peptide synthesis, such that hydroxyl groups protected with the azide-bearing protecting group remain protected during synthesis of the peptide chain. Various protecting groups which are readily available can be used for protecting potentially reactive side chain groups of amino acids in the peptide or protein to be modified.

Abstract: The present invention provides a process for the preparation of Avidin having a high purity of 98% from egg white, the said process comprising lyophilizing the homogenized egg white with buffer followed by equilibrating the lyophilized material with cation exchanger for an hour at a temperature range of 20° to 30° C.; filtering the mixture to obtain a filtrate and matrix residue; washing the matrix twice with buffer; separating the washings to obtain washed matrix; adding 0.01 M dye in buffer to the washed matrix; equilibrated for an hour at an ambient temperature; separating the supernatant; adding acetic acid to supernatant and dialysing the solution till it is decolorised to obtain pure Avidin.

Abstract: The dyes of formula (1) according to claim 1 and the copper complexes of dyes of formula (2) according to claim 9 or the mixtures of mono-copper complex with the bis-copper complex are excellently suitable for dyeing paper with good light-fastness properties.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: Methods and compositions regarding autocatalytic DNA strand exchange with a pre-defined target DNA are described herein. Specifically, single stranded DNA or double stranded DNA construct comprising preferably four definable sequences facilitate phospho-diesterase hydrolysis reactions and subsequent phosphodiesterification reactions or a transesterification reaction between the construct and a target DNA. The reactions require no mediation by protein catalytic mechanisms and are useful for therapeutic applications regarding genetically related diseases.

Abstract: Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tuberculosis to attenuate the pathogenic bacteria.

Abstract: The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.

Abstract: Synthetic processes are provided for the solution phase synthesis of oligonucleotides, especially phosphorothioate oligonucleotides, and intermediate compounds useful in the processes.

Abstract: A novel method has been found to produce 2,2′-anhydro-1-(&bgr;-L-arabinofuranosyl)thymine as a novel useful intermediate compound. A novel method has been further found to produce thymidine from 2,2′-anhydro-1-(&bgr;-L-arabinofuranosyl)thymine. A novel method has been further found to L-2′-deoxyribose derivatives as a useful synthetic intermediate through L-2,2′-anhydro-5,6-dihydrocyclouridine derivative. According to these methods, synthesis of various L-nucleic acid derivatives, synthesis of which has been difficult till now.

Abstract: The methods of the present invention prepare carrageenan products from processed seaweed material having a solids content of less than 25% by weight solids, using shear stress treatment. The carrageenan products comprise at least about 60% by weight of carrageenan and at least about 2% by weight of acid insoluble material. The carrageenan products of the present invention are useful as components in food products, such as, dairy products, meats, and dessert gels as well as non-food products, such as, toothpaste formulations, cosmetics, paints, films and delivery capsules.

Abstract: The present invention is a process for producing an aliphatic acid ester of carbohydrate comprising the steps of preparing an emulsion containing a salt of aliphatic acid and aqueous solution of carbohydrate or its derivative, obtaining a solid by removing water from said emulsion, and reacting said solid and an aliphatic acid ester.

Abstract: Novel &bgr;-lactam compounds represented by the following general formula (I) or pharmaceutically acceptable salts thereof which are useful as serum cholesterol-lowering agents: (I) wherein A1, A3 and A4 represent each hydrogen, halogen, C1-5 alkyl, C1-5 alkoxy, —COOR1, a group represented by the following general formula (b): (b) wherein R1 represents hydrogen or C1-5 alkyl, or a group represented by the following general formula (a): (a) wherein R2 represents —CH2OH, —CH2OC(O)—R1 or —CO2—R1; R3 represents —OH or —OC(O)—R1; R4 represents —(CH2)kR5(CH2)l— wherein k and l are each 0 or an integer of 1 or above provided k+l is an integer of not more than 10; and R5 represents a single bond, —CH═CH—, —OCH2—, carbonyl or —CH(OH)—; provided that at least one of A1, A3 and A4 is a group represented by the above formula (a); A2 represents C1-5 alkyl, C1-5 alkoxy, C1-5 alkenyl, C1-5 hydroxyalkyl or C1-5 car

Abstract: A novel process for the removal of impurities from clavulanic acid using a selective adsorption material, in particular a molecularly imprinted polymer. Novel selective adsorption materials suitable for the process, and a process for the preparation of such selective adsorption materials, are also disclosed.

Abstract: A process for synthesizing a compound represented by formula I: 1

Abstract: The instant invention relates to stable free nitroxyl radicals of formula (I) at least one of the substituents R is —O. and the others are hydrogen or OH; X is —NR1R2, wherein R1 and R2 are independently hydrogen, C1-C18alkyl or together with the nitrogen atom to which they are bound from a 5 or 6 membered ring which may be further interrupted by an O atom. Further subjects of the invention are an oxidation process for alcohols to aldehydes or ketones or to carboxylic acids in the presence of a compound of formula (I) and the use of stable free nitroxyl radicals of formula (I) as oxidation catalysts.

Abstract: This invention discloses a rubbery polymer which is comprised of repeat units that are derived from (1) at least one conjugated diolefin monomer, and (2) at least one functionalized monomer having of the structural formula: 1

Abstract: The invention relates to novel compounds which bind to integrin receptors, their use as ligands of integrin receptors, in particular as ligands of the &agr;v&bgr;3 integrin receptor, their use, and pharmaceutical preparations comprising these compounds.

Abstract: The present invention is to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]: 1

Abstract: A pyrimidine derivative compound of formula (I) or a salt thereof and a method for the preparation thereof.

Abstract: The invention relates to novel N-phenyl-4-(4-pyridyl)-2-pyrimidineamine derivatives of the general formula (1) wherein the sum of (m+p) together is 0, 1, 2 or 3; n and q are independently of each other 0 or 1, and the sum of (m+p+q) together is 1, 2, 3 or 4; R1 is hydrogen, halogen, alkoxy, haloalkyl, haloalkoxy or alkyl; R2 is hydrogen, C1-C6-alkyl, C1-C6-haloalkyl or C1-C6-alkoxy; R2A is hydrogen, C1-C6-alkyl, C3-C4-alkenyl or C3-C4-alkynyl; each of R3, R4, R5 and R6 is, independently of the others, hydrogen, C1-C6-alkyl, C1-C6-haloalkyl, hydroxy-C1-C6-alkyl or C1-C6-alkoxy-C1-C6-alkyl, or the ring members CR3R4 or CR5R6 or CR2R2A are independently of each other a carbonyl group (C═O) or a group C═S; X is C═O, C═S, S═O or O═S=O; Y is O, S, C═O, CH2A, —N(R8)—, —O—N(R8)—, —N(R8)—O— or NH—; R7 is hydrogen, C1-C4-alkyl, C3-C4-alkenyl, C3-C4-alkynyl, —CH2OR8, CH2SR8, —C(O)R8, —C(O)OR8,

Abstract: The invention is a process for producing haloalkyl pyrimidines as intermediates in the production of benzimidazole and/or pyridylimidazole derivatives having high selectivity and/or high affinity to the benzodiazepine site of GABAA receptors.

Abstract: The invention relates to a process for preparing hydroxyindolylglyoxylamides in high yields and particularly pure form.